CEBPZ and acute myeloid leukemia: Therapeutic strategies including gemtuzumab ozogamicin (GO) have shown comparable efficacy in patients with inv(16) rearrangements and those with t(8;21) fusions, suggesting that GO may be an effective addition in these CBF-AML subtypes [80].